Aberdeen medical device company gains US patents

A spin out of Aberdeen University has been granted two US patents for its bone graft technology.

The company, Sirakoss, already has patents in Europe, Japan, Australia and China, but the US rights will significantly further its efforts in the US market. The market, which is estimated to be worth $3 billion worldwide, will benefit the company’s product pipeline.

Sirakoss has designed synthetic material that has the potential to replace diseased of broken bone. The material would be used instead of autograft, a painful and invasive method where bone is harvested from other parts of the patient’s body.

Synthetic bone grafts are used following traumatic injuries where the bone fails to heal. They are common in trauma, spinal and dental surgery to fuse bones together to correct congenital or degenerative conditions.

The company’s calcium phosphate-based bone graft substitutes has gained encouraging surgeon feedback, the company state.

Brian Butchart, chief executive of Sirakoss, said: “The granting of these two patents endorses the breadth of our technology and provides Sirakoss further protection for its unique product offerings in the largest single market for bone graft substitutes.”